Medroxyprogesterone Acetate Injection, Suspension
NDC Package 55150-330-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Medroxyprogesterone Acetate injection is a medication used to prevent pregnancy. This formulation utilizes a injection, suspension delivery system. Marketed by Eugia Us Llc, this product is identified by NDC 55150-330 and is authorized under FDA application ANDA212844.

Identification & Billing

NDC Package Code
55150-330-01
Package Description
1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE
Product Code
11-Digit Billing Format
55150033001
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 1000126 - medroxyPROGESTERone acetate 150 MG in 1 ML Injection
  • RxCUI: 1000126 - 1 ML medroxyprogesterone acetate 150 MG/ML Injection
  • RxCUI: 1000126 - medroxyprogesterone acetate 150 MG per 1 ML Injection
  • RxCUI: 1000153 - medroxyPROGESTERone acetate 150 MG in 1 ML Prefilled Syringe
  • RxCUI: 1000153 - 1 ML medroxyprogesterone acetate 150 MG/ML Prefilled Syringe

Clinical Specifications

Proprietary Name
Medroxyprogesterone Acetate
Non-Proprietary Name
Medroxyprogesterone Acetate
Substance Name
Medroxyprogesterone Acetate
Dosage Form
Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route
Intramuscular - Administration within a muscle.
Usage Information
This medication is used to prevent pregnancy. Medroxyprogesterone is like a natural hormone made by the body. It works mainly by preventing the growth and release of an egg (ovulation) during your menstrual cycle. It also makes vaginal fluid thicker to help prevent sperm from reaching an egg (fertilization) and changes the lining of the uterus (womb) to prevent attachment of a fertilized egg. Medroxyprogesterone is also used to treat endometriosis. It works by lowering the amount of certain hormones in the body and decreasing the growth of abnormal tissues that cause endometriosis. This helps reduce pain and other symptoms. Using this medication does not protect you or your partner against sexually transmitted diseases (such as HIV, gonorrhea, chlamydia).

Regulatory & Marketing

Labeler Name
Eugia Us Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA212844
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-31-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Source: PDAC
INJECTION, MEDROXYPROGESTERONE ACETATE, 1 MG
HCPCS Dosage 1 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 55150-330-01 identifies a specific commercial package of 1 syringe in 1 carton / 1 ml in 1 syringe of Medroxyprogesterone Acetate, a human prescription drug labeled by Eugia Us Llc. This injection, suspension is formulated for intramuscular use and contains medroxyprogesterone acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eugia Us Llc on August 31, 2022. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to prevent pregnancy. Medroxyprogesterone is like a natural hormone made by the body. It works mainly by preventing the growth and release of an egg (ovulation) during your menstrual cycle. It also makes vaginal fluid thicker to help prevent sperm from reaching an egg (fertilization) and changes the lining of the uterus (womb) to prevent attachment of a fertilized egg. Medroxyprogesterone is also used to treat endometriosis. It works by lowering the amount of certain hormones in the body and decreasing the growth of abnormal tissues that cause endometriosis. This helps reduce pain and other symptoms. Using this medication does not protect you or your partner against sexually transmitted diseases (such as HIV, gonorrhea, chlamydia).

How is this Eugia Us Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 55150033001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
55150-330-01
11-Digit CMS (5-4-2)
55150-0330-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.